AR and neoplasm: Remarkably, MT 63–78 was shown to robustly enhance the anti-tumor effects of two AR antagonists that are utilized clinically (bicalutamide and enzalutamide), and this cooperative effect was observed both in cells that are sensitive to AR inhibition alone, as well as in CRPC models that are refractory to the AR antagonists as single agents.